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Pheochromocytomas (PC) and paragangliomas (PGL) are rare neural crest-derived 
tumours that occur at adrenal and extra-adrenal sites.  These tumours may be 
sporadic but a significant proportion are caused by familial syndromes due to 
germline mutations.  Mutations of the succinate dehydrogenase (SDH) complex 
make up the bulk of syndromic cases in the international literature.  SDH mutated 
cases are now known to have higher rates of metastatic disease, a younger age of 
onset, an association with other SDH mutated tumours as well as implications for 
first degree relatives.  An immunohistochemical stain for SDHB that has excellent 
correlation with SDH mutation status has been developed and is routinely used in 
many centres to infer SDH mutation status.  Loss of staining is seen when there is a 
mutation of any of the SDH subunit complexes.  The prevalence of SDH mutated 
tumours is not known in the South African setting.    
 
Methods 
A retrospective laboratory-based study was conducted at Tygerberg Hospital in 
South Africa to assess the prevalence of SDH deficiency in all PC and PGLs 
between 2005 and 2015.  These tumours were further stratified by other 
characteristics: tumour site, patient age, sex and presence of metastatic disease.  
Fifty-two cases met the inclusion criteria and the SDHB immunohistochemical stain 








Thirty-six percent of cases showed loss of staining of SDHB by 
immunohistochemistry.  Head and neck PGLs made up the bulk of cases (50%) and 
females were strongly represented, particularly at head and neck sites (73%).  Loss 
of staining was significantly correlated with a younger age at presentation (z = -3.59, 
p < .001).  There was no correlation between loss of staining and tumour site or 
patient sex.  The inter-observer agreement in interpretation of the 
immunohistochemical stain was excellent (Cohen’s kappa = 0.917, p < .001).      
 
Conclusion         
The prevalence of SDH deficiency in our setting, as shown by loss of 
immunohistochemical staining for SDHB, is comparable to the literature and makes 
up a significant proportion of our PC/PGL cases.  This highlights the need for 
performance of this stain in our setting in order to recognise these syndromic cases.  
Many patients in South Africa do not have access to genetic testing upon diagnosis 
of a PC or PGL as this is costly and not widely available.  Many studies have shown 
excellent correlation of the immunohistochemical stain with underlying SDH mutation 
status.  Immunohistochemistry is widely available in South African pathology 
laboratories and is relatively affordable.  Although interpretation of this stain can be 
challenging, we report excellent inter-observer agreement in a generalist pathology 
practice when following published guidelines for interpretation.  We therefore 










Feochromositome (FC) en paragangliome (PGL) is seldsame neurale kruin-afgeleide 
tumore wat voorkom in die byniere en buite die byniere respektiewelik. Hierdie 
gewasse kom meestal sporadies voor, maar 'n beduidende aantal gevalle word 
veroorsaak deur familiële sindrome as gevolg van kiemlynmutasies. Mutasies van 
die suksinaatdehidrogenase (SDH) -kompleks is verantwoordelik vir die meeste 
familiële sindrome in die internasionale literatuur. Dit is bekend dat SDH-gemuteerde 
gevalle ‘n hoër insidensie van metastases het, 'n jonger ouderdom van aanvang, 
geassosieer is met ander SDH-gemuteerde gewasse, en ook implikasies mag inhou 
vir eerstegraadse familielede. 'n Immunohistochemiese kleuring vir SDHB wat 'n 
uitstekende korrelasie met SDH-mutasie-status het, is ontwikkel en word 
roetinegewys in baie sentrums gebruik om die SDH-mutasie-status af te lei. Verlies 
van kleuring word gesien as daar 'n mutasie van enige van die SDH-
subeenheidskomplekse is. Die prevalensie van SDH-gemuteerde tumour is nie 
bekend in die Suid-Afrikaanse konteks nie. 
 
Metodes 
'n Retrospektiewe laboratoriumgebaseerde studie is in die Tygerberg-hospitaal in 
Suid-Afrika gedoen om die prevalensie van SDH-gebrek in alle FC en PGL tussen 
2005 en 2015 te bepaal. Hierdie tumore is verder gestratifiseer deur ander 
eienskappe: anatomiese verspreiding, pasiëntouderdom, geslag en teenwoordigheid 
van metastatiese siektes. Twee-en-vyftig gevalle het aan die insluitingskriteria 




uitgevoer. Daar is nie 'n kiemlyntoetse of nukleotied-volgorde bepaling van hierdie 




Ses-en-dertig persent van die gevalle het verlies van kleuring van SDHB deur 
immunohistochemie getoon. PG van die kop en nek het die grootste gedeelte van 
gevalle uitgemaak (50%) en die vroulike geslag was die meeste verteenwoordig, 
veral in die kop- en nektumore (73%). Die verlies van kleuring was beduidend 
gekorreleer met 'n jonger ouderdom van presentasie (z = -3.59, p <.001). Daar was 
geen verband tussen verlies van kleuring en anatomiese verspreiding of geslag nie. 
Die ooreenkoms in die interpretasie van die immunohistochemiese kleuring tussen 
waarnemers was uitstekend (Cohen se kappa = 0,917, p <0,001). 
 
Gevolgtrekking 
Die voorkoms van SDH-mutasies in ons konteks, soos aangetoon deur die verlies 
van immunohistochemiese kleuring vir SDHB, is vergelykbaar met die literatuur en 
maak 'n beduidende deel van ons FC / PGL-gevalle uit. Dit beklemtoon die behoefte 
aan die uitvoering van hierdie kleuring in ons praktyk om hierdie sindroomgevalle te 
herken. Baie pasiënte in Suid-Afrika het nie toegang tot genetiese toetsing tydens 
die diagnose van 'n FC of 'n PGL nie, aangesien dit duur is en nie algemeen 
beskikbaar is nie. Baie studies het uitstekende korrelasie van die 
immunohistochemiese kleuring met die onderliggende SDH-mutasie-status getoon. 
Immunohistochemie is algemeen beskikbaar in Suid-Afrikaanse patologie 




uitdagend kan wees, rapporteer ons 'n uitstekende ooreenkoms tussen waarnemers 
in 'n algemene patologiepraktyk wanneer gepubliseerde riglyne vir interpretasie 
gevolg word. Ons stel dus voor dat hierdie kleuring roetinegewys gedoen word in alle 
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Paragangliomas (PGLs) and pheochromocytomas (PCs) are neural crest-derived 
tumours that occur at adrenal and extra-adrenal sites.  These tumours may be 
sporadic or associated with familial syndromes.  Mutations of succinate 
dehydrogenase, a mitochondrial complex, has been demonstrated to be the genetic 
basis for the familial pheochromocytoma/paraganglioma syndrome.  This syndrome 
makes up the majority of familial syndromic cases and tumours with mutations in 
specific subunits of the SDH complex occur at younger ages, are more likely to 
metastasize and may be associated with other syndrome associated tumours.  
Recognition of these cases is therefore important for prognostic and management 
purposes.  Germline genetic testing is expensive and not widely available.  An 
immunohistochemical stain against the SDHB complex was developed and loss of 
staining has shown excellent correlation with SDH mutation status.      
 
Purpose of Study 
The purpose of this study was to demonstrate what proportion of cases of PG/PGL in 
our setting are associated with SDH mutation by using IHC as a surrogate marker for 
SDH mutation status.  We also aimed to describe the characteristics of these 
tumours in our setting including patient age, sex, tumour site and presence or 
absence of metastatic disease.  Since this immunohistochemical stain was not yet 
available in our setting we aimed to acquire and optimise the stain and then assess 
the inter-observer variability in interpretation of the stain in order to infer its potential 









PC and PGL are rare neural crest-derived tumours that arise in the adrenal medulla 
and sympathetic or parasympathetic ganglia.1,2   The World Health Organisation 
(WHO) 4th edition classification of endocrine tumours (2017) defines PC as a tumour 
of chromaffin cells that arises in the adrenal medulla.1  Extra-adrenal PGLs are 
defined by the WHO as tumours originating from neural crest-derived paraganglion 
cells in the region of the autonomic nervous system ganglia and autonomic nerves.1  
Sympathetic PGLs are catecholamine secreting tumours and include those in the 
adrenal gland (PC) as well as extra-adrenal sites, predominantly the thorax and 
abdomen (thoraco-abdominal PGLs - TAPGLs).1,2   Parasympathetic PGLs are 
extra-adrenal, do not secrete catecholamines and occur predominantly in the head 
and neck region (head and neck PGLs - HNPGLs).2   
 
PGLs and PCs can occur sporadically or as hereditary tumours with up to 40% 
occurring as a result of germline mutations in susceptibility genes.2,3   Up to 15% of 
apparently sporadic tumours have somatic mutations.4,5  Currently ten such 
susceptibility genes have been described, all of which function as tumour suppressor 
genes with tumours showing loss of heterozygosity in combination with germline 
inactivating mutations.5–9   PC/PGLs resulting from any of these mutations are 
histologically indistinguishable and there are no reliable histological features that 
predict malignancy.10  Malignancy in PC and PGLs has been difficult to define and 




According to the most recent WHO guideline, the preferred terminology is now 
‘metastatic’ PGL/PC rather than ‘malignant’.1 
 
2.2. Hereditary syndromes associated with PC/PGL 
 
Research conducted in the 19th and 20th centuries led to the recognition of three 
PC/PGL-associated syndromes.11  These include von Hippel-Lindau (VHL) disease, 
Multiple Endocrine Neoplasia type 2 (RET) and Neurofibromatosis type 1 (NF1).12–16  
Between 2000 and 2010, the molecular basis for hereditary PC/PGL syndrome was 
discovered to be due to mutations in succinate dehydrogenase (SDH) subunits and 
related genes.6–10,17,18  Following this discovery of the genetic basis of hereditary 
PC/PGL syndrome, other tumours with a lower penetrance including gastrointestinal 
stromal tumours (GIST), renal cell carcinomas and pituitary tumours, were found to 
be part of the full tumour spectrum of this genetic defect.11   New susceptibility genes 
causing hereditary PC/PGL syndrome discovered over the past ten years include 
MAX, TMEM127, EGLN, HIF2α, MET and KIF1B.2 
 
Currently these susceptibility genes are grouped into two categories; Major 
susceptibility genes including NF1, VHL, RET and SHDB/D and minor susceptibility 
genes including SDHA/C, SDHAF2, MAX, TMEM127.5  The major susceptibility 
genes account for up to 90% of the hereditary tumours, the minor group accounts for 






2.3. Significance of determination of the genetic phenotype 
 
The importance of determining the genetic phenotype of these tumours is two-fold: 
detection of syndromic cases and prognostication.  Tumour genotypes have now 
been linked to specific tumour phenotypes such as their biochemical behaviour, site, 
clinical presentation, potential to metastasize as well as therapeutic responses.5   
Knowledge of the specific tumour genotype can therefore aid in further management 
of the patient in terms of prognosis, screening for other tumours, choice of therapy, 
genetic counselling for first degree relatives and perhaps most importantly assessing 
the risk of malignancy.5,19   Although there are as yet no large trials showing data to 
support genotype specific therapy for metastatic disease, it has been shown that 
patients with mutations of SDHB respond well to CVD (cyclophosphamide, 
vincristine and dacarbazine) chemotherapy.5 
 
Due to the above mentioned factors it is the current view of many authors that 
genetic testing should be offered to all patients with PC/PGL.5   The major limiting 
factor in many settings is the cost of performing such broad genetic screening.   
Research which demonstrates links between genotype and clinical/biochemical 
phenotype therefore provides a means for clinicians to stratify patients based on the 
available data in order to more selectively perform genetic testing according to 
algorithmic approaches.  
 
2.4. Succinate dehydrogenase deficiency 
 
The succinate dehydrogenase enzyme complex (mitochondrial complex II) catalyses 




with inactivating germline mutations results in lack of the SDH enzyme and 
destabilisation of the SDH protein complex leading to an accumulation of 
succinate.18,20–22  This results in reactive oxygen species with free radical damage as 
well as disturbance of hypoxia inducible factor alpha (HIFα).18,20–22   The complex 
consists of four subunits (see Figure 1) – SDHA, SDHB, SDHC and SDHD, any of 
which may be causative in hereditary PC/PGL.5,17,23  SDHAF2, a mitochondrial 
protein which flavinates SDHA, is essential for formation of the SDH complex and is 
also implicated in familial PC/PGLs when mutated.18,24    
 
 
Figure 1. Structure and function of the succinate dehydrogenase complex   
– included with the authors permission23 
 
Currently the PGL syndromes associated with SDH-mutations are grouped into five 
types according to the subunit which is mutated (see table 1).  Each of these groups, 
numbered PGL1-5, are associated with a different spectrum of SDH-related tumours 




Table 1. SDH associated familial paraganglioma syndromes 
Syndrome PGL1 PGL2 PGL3 PGL4 PGL5 
SDH 
subunit 


















The reported rate of SDH mutations in PGLs varies significantly between series, 
between 15% and 54%.17,25   Mutations in SDHB and D are the most common of the 
four subunits and correspond to syndromes PGL4 and PGL1 respectively.2  SDHB 
mutated tumours (PGL4) are usually abdominal and have the highest risk of 
metastases.  Up to 71% of paragangliomas with SDHB mutations have been shown 
to metastasize compared to only 3% of non-SDH mutated cases.10,17  Furthermore, 
SDHB mutations, which show incomplete penetrance, result in tumours at younger 
ages.26  In contrast, tumours with SDHD mutations are typically found in the head 
and neck region, are multiple and recurrent with a very low rate of metastases.2 
 
According to the SDH mutation database (an online resource capturing all reported 
SDH sequence variants involved in PC/PGL) up to 289 sequence variants of SDHB 
have currently been described with the majority of these mutations being missense 
mutations.27  
 
2.5. Mechanisms of tumorigenesis in SDH deficient tumours 
 
As mentioned above, mutations in SDH result in failure to inactivate  HIFα.28   




entirely clear, activation of the hypoxia response pathway is believed to play a role.  
Accumulation of succinate results in triggering of downstream signals that simulate 
hypoxia resulting in expression of genes involved in angiogenesis.28–31     
 
2.6. Head and neck PGLs 
 
Head and neck PGLs account for the majority of PGLs and have exceptionally high 
rates of SDH mutations with Mannelli reporting a rate of 31%.32  SDHD mutations are 
the most common of the SDH mutations in HNPGLs.32–34  Tumours with SDHD 
mutations have higher rates of multifocality than tumours due to other SDH 
mutations.33,34  SDHD mutations also occur in apparently sporadic HNPGLs.34  
SDHD is maternally imprinted and therefore tumours only develop when the gene is 
paternally inherited (parent of origin mode of inheritance).10,32,34   This pattern of 
inheritance is not seen with SDHA and SDHB. 
 
2.7. Thoraco-abdominal PGLs 
 
TAPGLs are not as common as PCs and HNPGLs however their rate of malignancy 
is high.32   TAPGL were found to be associated with SDH mutations in 33%32 and 
41%35 of cases in two studies.  The majority of these mutations were of SDHB.32,35  
As stated previously SDHB mutation are associated with high rates of metastases 







2.8. Spinal paragangliomas 
 
Central nervous system PGLs are rare tumours that most often occur in the cauda 
equina region of the spinal canal.  Little information is available regarding the 
association of spinal PGLs with SDH mutations or with other PGL associated 
syndromes.  A study that investigated 22 spinal PGLs for SDHD mutations showed 




The rate of SDH mutations in PCs ranges from 2.8%32 to 4.5%35 with equal numbers 
attributable to SDHB and SDHD.  These patients develop tumours at a younger age 
and have higher rates of bilateral disease.10 
 
2.10. Immunohistochemistry (IHC) for SDHB 
 
Despite algorithmic approaches to better target patients for specific genetic testing 
and thereby reduce costs, the burden of genetic screening is still high.19  In 2009 it 
was reported that IHC for SDHB could be used to identify cases with underlying SDH 
germline mutations.38  Destabilisation of any of the four subunits of SDH can be 
detected by immunohistochemical analysis for SDHB.38  SDHB 
immunohistochemistry has therefore emerged as a more cost effective method to 
‘triage’ genetic testing of SDH genes as it selects out patients who can then undergo 





Inactivation of any of the SDH genes (A, B, C or D) result in loss of enzymatic activity 
and therefore loss of staining of SDHB.  Negative staining indicates that any of the 
four subunits of SDH may be mutated and then allows for further more targeted 
genetic testing.19  Several studies have demonstrated that SDH IHC has a high 
diagnostic accuracy (sensitivity and specificity of up to 100% reported in some 
studies)with low inter-observer variability and with a good negative predictive 
value.19,38  A large study using web based virtual microscopy showed substantial 
inter-observer agreement in interpretation of SDHB immunohistochemistry with 
kappa values of 0.7338.39   
 
Mutations of one of the SDH subunits are almost always due to a germline mutation 
and are very rarely somatic.39–42  The detection of these cases is therefore of 
paramount importance as loss of immunohistochemical staining in these cases 
therefore signifies likely syndromic disease due to germline SDH mutations or more 
rarely, hypermethylation of SDHC.43 
 
2.11. Interpretation and reporting of SDHB IHC 
 
Correct interpretation of SDHB IHC is crucial if it is to be a useful diagnostic tool.  
There are potential pitfalls in interpretation and strict guidelines for correct 
interpretation have been advised.10,44   SDHB IHC should be interpreted as 
positive/retained if the staining is granular cytoplasmic within the tumour cells (as it is 
a mitochondrial enzyme), even if this staining is patchy.  Negative staining or loss of 
staining is demonstrated by loss of cytoplasmic staining in the tumour cells with 
retention of staining in sustentacular cells and endothelium (positive internal 




negative/lost.  Staining is said to be equivocal if there is a cytoplasmic blush or only 
focal positivity.  False negatives can be avoided by well-defined internal controls and 
following clear and strict protocols.  
 
Conventional “positive” and “negative” descriptors used when reporting the results of 
immunohistochemical staining can be confusing when applied to stains where 
positive staining is a normal result and negative staining is abnormal. It is therefore 
advised that these results should be clearly reported in the pathology report as 
normal intact staining or abnormal loss of staining.45  
 
2.12. SDH deficiency in South Africa 
 
Currently the percentage of PC/PGLs with mutations of SDH in our setting is 
unknown.  To the authors’ knowledge no published studies have been conducted in 
South Africa to determine if the prevalence rates locally are comparable to that 




We hypothesize that the prevalence of SDH deficiency in PC and PGLs at Tygerberg 








3.1. Primary aim 
 
The main aim of this study was to determine the prevalence of succinate 
dehydrogenase deficiency based on loss of immunohistochemical staining for SDHB 
in biopsy and resection specimens of PGL and PC between 2005 and 2015 at 
Tygerberg Hospital in Cape Town. 
 
3.2. Secondary aims 
 
The secondary aims were to stratify paragangliomas by their location/site into 
HNPGL, TAPGL and other and to compare the prevalence of loss of staining of 
SDHB by site. 
Other aims were to compare SDH status with clinical parameters including age, sex 
and clinical behaviour and to assess the inter-observer agreement in interpretation of 
the immunohistochemical stain. 
 
3.3. Motivation for this study 
 
Currently the percentage of PC/PGL with mutations of SDH in our setting is 
unknown.  If the prevalence is found to be equivalent to studies conducted 
elsewhere, then genetic and IHC testing for the mutation on a routine basis might 
prove valuable.  As discussed above the implications of loss of SDH staining are of 
prognostic value and allow for recognition of syndromic cases.  Early detection of 
syndromic disease in individual patients and their family members with screening for 




implications.  Immunohistochemistry is widely available in South Africa, relatively 
easy to perform and interpret and significantly more cost effective than genetic 
testing.  Development of this test in our setting, once the prevalence is known, is 













4.1.1. Study design 
This was a retrospective descriptive laboratory-based study. 
 
4.1.2. Inclusion criteria 
Biopsy and resection specimens from patients diagnosed with PGL and/or PC 
between 2005 and 2015 at Tygerberg Hospital were included.    
 
4.1.3. Exclusion criteria 
Cases of PGL and PC where the tissue wax blocks could not be retrieved from the 
archive were excluded from this study.  Cases in which there was disagreement 
about the diagnosis of PC/PGL upon review were also excluded.  
 
4.1.4. Sample size 
A total of 65 cases of PC/PGL between 2005 and 2015 were identified.  Four 
patients had multiple specimens of PC/PGL, either recurrences or metastases (three 
patients had three cases each, one patient had two cases).  Only one case per 
patient was included as SDH mutations are almost exclusively germline and the 
presence of an SDH mutation would therefore be present in all PC/PGLs from the 
same patient.  A total of 58 patients were therefore identified.  A further six cases 
were excluded – one in which the preferred diagnosis was a neuroendocrine tumour 
and five for which the wax blocks could not be retrieved.  A total of 52 cases were 






Figure 2. Flow diagram of the case selection process. 
   
4.2. Detailed methods 
 
4.2.1. Specimen retrieval 
Specimens were identified on the DISA laboratory system with key word search 
and/or Snomed codes for PC and PGL.  The slides and tissue blocks were retrieved 
from the archive at the Division of Anatomical Pathology, National Health Laboratory 





4.2.2. Tissue wax block selection and histopathological evaluation 
All the available histopathology slides of each case included in the study were 
reviewed by the PI (CBB) together with a consultant anatomical pathologist (AvW).  If 
the diagnosis was agreed upon, a tissue block was selected for 
immunohistochemical staining.  If tumour was present in more than one block the 
most appropriate block in terms of quality and quantity of tumour was selected for 
further immunohistochemical staining.  Where possible, blocks were chosen that 
also included some normal background tissue to assist with inclusion of internal 
controls.  Cases for which tissue wax blocks could not be retrieved (five cases) or in 
which there was uncertainty about the diagnosis (one case) were excluded.   
 
  
a) Haematoxylin and eosin stained 
section, 100x magnification: 
paraganglioma in a patient with 
confirmed SDH mutation. 
b) SDHB immunohistochemistry 
showing loss of staining in the 
tumour cells with retained granular 
cytoplasmic staining in the 
endothelial cells (internal control), 
see arrow. 
Figure 3. Paraganglioma in a patient with confirmed SDH mutation.  
 
4.2.3. Immunohistochemical staining for SDHB 
SDHB immunohistochemical staining was performed on an automated 




operating procedures (SOP) and the manufacturer’s instructions.  Two SDHB 
antibodies were acquired for optimisation in our laboratory as this stain was not yet 
available to the NHLS.  The initial antibody acquired was from ABCAM (rabbit 
polyclonal IgG, ab151684).  Numerous attempts to optimize this stain were 
performed but our laboratory was unable to achieve a consistent result with 
appropriate positive internal controls using this antibody.  A second antibody was 
then acquired from Sigma Aldrich (rabbit polyclonal IgG, HPA002868 antibody) 
which was successfully optimised at dilutions of 1:400 with antigen retrieval using 
heat.  The commercially available ER2 heat induced epitope retrieval was used 
which has a pH of 8.9-9.1 and is EDTA based. The epitope retrieval was applied for 
20 minutes at 100 degrees Celsius.  This stain was validated using two cases of 
PGLs in which the SDH mutation status of the patients was known (germline testing 
had been performed).  In the case in which the patient was known to have an SDH 
mutation the immunohistochemistry showed loss of staining as expected (Figure 3).  
In the case in which the patient had no SDH mutation by germline testing the 
immunohistochemistry showed retention of staining (Figure 4). 
 
The following steps were followed in our laboratory according to our SOP.  Tissue 
sections were cut at 3-5µm and placed onto super frost plus slides.  The slides were 
then baked for 30 minutes at 70°C.  Slides were then placed into the BOND 
automated staining machine which was run according to manufacturer’s instructions 
(see table 2).  Bond wash was prepared by adding 100 ml of BOND Wash 
concentration to 900ml of deionised water.  The slides were placed in a DAB 
enhancer for 4 minutes.  The slides were then dehydrated in a series of graded 





a) Haematoxylin and eosin stained 
section, 40x magnification: 
pheochromocytoma in a patient 
with no SDH mutation on germline 
testing. 
b) SDH immunohistochemistry 
showing retained granular 
cytoplasmic staining in the tumour 
cells. 
Figure 4. Pheochromocytoma in a patient with no SDH mutation on 
germline testing. 
 
4.2.4. Interpretation of the IHC stain 
Positive staining/normal retained staining was interpreted as granular cytoplasmic 
staining in the tumour cells.  Any amount of positive staining was interpreted as 
retained staining.  Negative staining/loss of staining was interpreted as complete 
absence of cytoplasmic staining in the tumour cells with positive staining of the 
external and internal controls.  Internal controls included sustentacular cells and 
endothelial cells.  The IHC stains were interpreted by the PI and a consultant 





Table 2. Leica Bond III staining protocol.  
 Repeats/cycles Time Temperature 
Dewax X3  72˚C 
100% Alcohol X3   
Bond wash X3   
Retrieval SDHB X2 20 min 100˚C 
Bond wash X4   
Bond wash X1 3 min  
Optimally diluted antibody X1 15 min  
Bond wash X1 2 min  
Bond wash X2 1 min  
Post primary X1 8 min  
Wash  X3   
Polymer  X1 8 min  
Wash  X2 2 min  
Deionized water X1   
Peroxide block X1 5 min  
Wash  X1 1 min  
Wash  X2   
Distilled water X1   
Mixed DAB refine X1   
Mixed DAB refine X1 10 min  
Deionized water X3   
Haematoxylin X1 5 min  
Deionized water X1   
Wash  X1   
Deionized water X1   
    
4.2.5. Data management 
Electronic capturing of de-identified data was performed on a password protected 
Excel spreadsheet which only the PI and supervisor had access to.  Cases were 




metastatic disease.   The information required to perform this stratification was 
obtained from the pathology laboratory information system.  A unique random study 
number was assigned to each pathology specimen. This study number as well as 
age, site of tumour, presence of metastases and loss or retention of SHDB staining 
was captured on the Excel spreadsheet.  
 
4.2.6. Security and backup 
The Excel spreadsheet was password protected and only the PI and supervisor had 
access to this password.  The document was saved on the PI’s computer which was 
locked in an access-controlled office.  On-line backup of the spreadsheet was 
performed using Google Drive (also password protected). 
 
4.2.7. Statistical considerations 
Data was analysed using SPSS (Version 25) with the threshold for significance set at 
p = 0.05. Data was presented as means and standard deviations for continuous 
variables, and proportions for categorical data. A Mann-Whitney U test was used to 
compare the median age of patients who had retention and loss of staining. Chi-
square tests were used to determine if there was an association between retention of 
staining and (a) sex, and (b) site of tumour. Inter-observer reliability for coding of 
retained or lost staining was assessed using Cohen’s kappa.  
 
4.3. Ethical considerations 
 
4.3.1. Waiver of consent 
A waiver of consent was requested to review the PGL and PC biopsy/resection 
specimens as well as to perform additional immunohistochemical stains (SDHB) on 




result of the immunohistochemically staining would in no way influence the current 
clinical management/care of the patient and therefore involved minimal risk.  The 
SDH immunohistochemistry was performed on the tumour only with no germline 
testing performed in this study.  The two cases used for validation of the 
immunohistochemical staining had given informed consent to the clinical team for 
performance of germline testing which was not performed as part of this study but as 
part of the patients’ clinical management.  The practicality of attempting to obtain 
consent from patients/relatives of the cases sampled over a ten-year period would 
make this study impossible to perform.  Procedures to protect confidentiality were 
maintained throughout the study. 
 
4.3.2. Confidentiality 
Strict patient confidentiality was maintained throughout this study.   Specimens were 
de-identified and assigned unique study numbers.  Only the PI and supervisor had 
access to the cases and to the data which was password protected and kept in an 
access-controlled office at all times.   
 
4.3.3. Ethics approval 
This study received ethical approval from the Stellenbosch University Health 
Research Ethics Committee (HREC) on 14 March 2017 (reference number: 
S17/02/041).  An annual renewal of ethics approval was obtained from the HREC 
following submission of annual progress reports. 
 
4.4. Funding 
Funding for this study was obtained from the NHLS Research Trust Development 






A total of 65 cases of PC/PGL between 2005 and 2015 were identified.  Four 
patients had multiple specimens of PC/PGL, either recurrences or metastases.  Only 
one case per patient was included.  A total of 58 patients were therefore identified.  A 
further six cases were excluded – one in which the diagnosis was disputed and five 
for which the wax blocks could not be retrieved.  A total of 52 cases were therefore 
included in the final sample (figure 2). 
 
 
Figure 5. Diagrammatic representation of head and neck tumours by 
specific site. 
 
The mean age of the patients included was 41.8 years (SD =16.4 years; range: 7 – 
71 years).  Females were more strongly represented with thirty-four females (65%) 
and eighteen males.   Tumours located in the head and neck region made up 50% of 




followed by jugulo-tympanic tumours (38%) (See figure 5).  Other head and neck 
sites included neck (not further specified), laryngeal and skull (not further specified).  
Thoraco-abdominal cases made up 46% of the sample (n=24) with the majority 
occurring in the adrenal gland (58%) and para-aortic sites (25%) (See figure 6).  
Other thoraco-abdominal sites included liver, pelvic and retroperitoneal (not further 
specified).  The remainder of the cases were spinal (4%, n=2, see figure 7).  A total 
of three patients (6%) had metastatic disease. 
 
 







Figure 7. Diagrammatic representation of tumours by site.  
 
Loss of SDHB staining was present in 36% of cases (n=19).  Retained staining was 
therefore seen in 64% (n = 33) and no cases were excluded for equivocal staining 
(See figure 8 and 9).  Patients who had loss of staining were significantly younger 
than those who had retained staining (z = -3.59, p < .001). The median age of those 
who showed loss of staining was 26 years (IQR: 21 – 41), compared to 50.5 years 
(IQR: 36 – 61) for those who showed retained staining (see table 3).  Sex was not 
associated with loss of staining (χ2 = 2.15, p = .142), with 9 of the 18 males (50%) 
compared to 10 of the 34 females (29.4%) showing loss of staining. Site of tumour 
was also not associated with loss of staining (χ2 = 0.94, p = .333), with 7 of the 24 
TAPGLs (29.2%) compared to 11 of the 26 HNPGLs (42.3%) showing loss of 






a) Haematoxylin and eosin stained 
section, 100x magnification: 
adrenal pheochromocytoma. 
b) SDHB immunohistochemical 
stain of (a) showing retained 
staining with granular cytoplasmic 
staining.   
  
c) Haematoxylin and eosin stained 
section, 40x magnification: jugulo-
tympanic paraganglioma. 
d)  SDHB immunohistochemical 
stain of (c) showing retained 
staining with granular cytoplasmic 
staining. 
Figure 8. Pheochromocytoma and paraganglioma with retained SDHB 







a) Haematoxylin and eosin stained 
section, 40x magnification: 
metastatic paraganglioma in the 
liver, note the tumour (left) and the 
background liver parenchyma 
(bottom right).   
b) SDHB immunohistochemical 
stain showing loss of staining in 
the tumour in (a) (bottom) with 
granular cytoplasmic staining in the 
adjacent hepatic parenchyma (top).  
  
c) Haematoxylin and eosin stained 
section, 40x magnification: carotid 
body paraganglioma.   
d) Chromogranin-A, granular 
cytoplasmic staining in the carotid 





e) S100 immunohistochemistry 
showing sustentacular cells around 
nests of tumour cells in the 
paraganglioma seen in (c).   
f) SDHB immunohistochemical 
stain showing loss of staining in 
the tumour with retained granular 
cytoplasmic staining in 
sustentacular and endothelial cells 
(arrow). 
Figure 9. Paragangliomas with loss of SDHB immunohistochemical 
staining. 
 
Interpretation of the IHC stain was performed by the PI and a consultant anatomical 
pathologist independently.  The inter-observer agreement between the two 
interpreters was excellent (Cohen’s kappa = 0.917, p < .001).    
 
 
Table 3.  Loss of immunohistochemical staining by age. 
Staining Loss of staining Retention of staining 
Mean age 26 years (IQR: 21 – 41) 50.5 years (IQR: 36 – 61) 




Table 4. Cases with loss of immunohistochemical staining by site. 
Tumour site HNPGL TAPGL Spinal PGL 
Number  26 24 2 
Number with loss 
of staining 
11 (42.3%) 7 (29.2%) 1 (50%) 




















All tumours 14 6 4 13 10 3 2 
SDHB lost 1 (7%) 3 (50%) 3 (75%) 7 (54%) 4 (40%) 0 1 (50%) 
Age (mean) 23 16-26 (20) 7-53 (33) 24-55 (36) 21-47 (29) - 40 
Sex (M/F) 1/0 1/2 2/1 2/5 2/2 - 1/0 
SDHB retained 13 (93%) 3 (50%) 1 (25%) 6 (46%) 6 (60%) 3 (100%) 1 (50%) 
Age (mean) 19-67 (45) 44-49 (47) 43 22-71 (49) 27-68 (49) 36-65 (54) 57 







6.1. Study design 
 
This was a retrospective descriptive laboratory-based study.  Cases were identified 
from the NHLS archives at Tygerberg Hospital using the laboratory electronic 
information system (DISA).  Cases diagnosed as PC or PGL between 2005 and 
2015 were selected using key word searching.  The cases identified were assigned 
unique study numbers and captured on a password protected Excel spreadsheet.  
Cases for which there was disagreement about the diagnosis (1 case), or for which 
the wax blocks could not be retrieved (5 cases), were excluded.  Four patients had 
multiple specimens and only one case per patient was selected for inclusion.  A total 
of 52 cases meeting inclusion criteria were identified. 
 
The histology (haematoxylin and eosin stained slides) of each case was reviewed by 
the PI and a consultant anatomical pathologist (AvW).  Any additional 
immunohistochemical or histochemical stains that were performed at the time of 
diagnosis and that were available were reviewed.  Wax blocks were selected during 
this review process on which to perform immunohistochemistry.  An attempt was 
made in all included cases to utilise the most appropriate wax block based on quality 
and amount of tumour present as well as the presence of adjacent normal tissue to 
act as positive internal controls. 
 
Immunohistochemistry was performed on the selected wax blocks according to the 
laboratory SOP using the Leica BOND III as described above (methods).  The initial 




consistent result with appropriate positive and negative controls was not achieved 
despite multiple attempts over a period of a few months.  A second antibody was 
then acquired from Sigma Aldrich and successfully optimised and validated using 
two cases with known positive and negative germline testing for SDH mutations. 
 
The immunohistochemistry was interpreted independently by the PI and AvW with 
cases blinded by their unique study number.  The interpretation of the staining was 
then compared between the two interpreters.  Interpreters followed the guidelines for 
interpretation of retention/loss of staining as outlined in more detail above (see 
methods).  In only two of the fifty-two cases was there initial disagreement in 
interpretation.  These two cases were then reviewed again by the two interpreters 
together and a consensus was reached.  In both of these cases, upon review of the 
interpretation criteria and re-screening of the slide the interpreters agreed on 
retained/lost staining. 
 
Germline testing for SDH mutation or sequencing of the tumours was not performed 
in this study and this data was not available for any of the included cases.  Two 
cases used to validate the immunohistochemical staining had this information 
available (one with a known germline SDH mutation and one with no SDH mutation).  
These cases were diagnosed outside of the time frame (2005-2015) used for this 
study and were therefore not included. 
     
6.2. Demographics 
 
The age range of patients included in this study was broad.  The youngest patient 




is similar to what is reported in the literature.46–49  The WHO Classification of tumours 
of Endocrine organs reports a mean age of 41-47 years.1  
 
Females made up the majority of patients included in this study.  Thirty-four of the 
fifty-two patients were female (65%) compared to only eighteen males.  Of the head 
and neck PGLs, 73% occurred in females.  This is reflected in the literature with a 
reported female to male ratio of 8:1 for HNPGL, particularly at high altitudes.50,51  
Information regarding the altitude at which patients lived was not available, however 
our setting is coastal with a low altitude.      
 
6.3. Tumour site 
 
Fifty percent of cases included in this study were paragangliomas occurring within 
the head and neck region.  The most common site within the head and neck was the 
carotid body (50% of cases), followed by jugulo-tympanic tumours (38%).  This is 
comparable to the literature which reports carotid body PGLs as the most common 
site in the head and neck (57%).47,49  Only one laryngeal tumour was identified.  
Laryngeal PGLs are known to be exceptionally rare.47,49  In the remainder of the 
HNPGLs the site listed was not specific enough to classify further such as ‘neck’ and 
‘skull’.    
 
Forty-six percent of the included cases were TAPGLs with the majority, 58%, 
represented by PC (adrenal tumours).  The mean age of patients with adrenal 
tumours was 44 years and the male to female ratio was roughly equal, similar to 
what is reported in the WHO Classification of Endocrine tumours.  Other thoraco-




6.4. Presence of metastatic disease 
 
Information regarding the presence of metastatic disease was only available for 
three patients.  This did not allow for any statistically significant correlations to be 
drawn.  It is however noted that all three of these patients did have loss of staining of 




Loss of SDH staining was present in 36% of cases.  This falls within the range 
reported in the literature of 15-54%.17,25  Loss of staining was significantly correlated 
with a younger age at presentation (z = -3.59, p < .001). The median age of those 
who had retained staining was 50.5 years (IQR: 36 – 61), compared to 26 years 
(IQR: 21 – 41) for those who showed loss of staining.  This is supported by the 
literature with patients known to have SDH mutations developing disease at 
significantly younger ages than those in whom disease is sporadic.26  
 
Sex was not associated with loss of staining (χ2 = 2.15, p = .142).  Familial PGL/PC 
syndromes caused by SDH mutations have an equal sex distribution and therefore 
this association would not be expected. 
 
The site of tumour was also not associated with loss of staining (χ2 = 0.94, p = .333).  
Since loss of staining for SDHB will be present if there is mutation of any of the SDH 
subunits, this association would also not be expected.  On germline testing tumour 
site should correlate with specific SDH subunit mutation (with SDHB most common 





6.6. Inter-observer variability 
 
Interpretation of the IHC stain was performed by the PI and a consultant anatomical 
pathologist independently.  Once interpretation was completed independently the 
results were compared and any cases that were initially disagreed upon were 
reviewed again together to come to a consensus.  Only two cases were interpreted 
differently on initial review.  Following review of these two cases together, a 
consensus was easily reached in both cases.  The inter-observer agreement 
between the two interpreters was excellent (Cohen’s kappa = 0.917, p < .001).  This 
inter-observer agreement is similar to what has been reported in the literature.  Of 
note the reported excellent inter-observer agreement in the literature was in a setting 
with sub-specialist endocrine pathologists.39  The two interpreters in this study had 
no prior experience with this stain and are general pathologists.  We acknowledge 
that interpretation of this stain can be difficult as it requires identification of loss of a 
granular cytoplasmic stain.  However, our excellent inter-observer variability 
demonstrates that following strict and clear guidelines should allow accurate 
interpretation of this stain by other general pathologists in our setting.    
 
The prevalence of SDH loss in our setting is comparable to the literature and 
highlights the need for performance of this stain in our setting. While multigene panel 
germline testing will probably become more accessible and cost-effective and may 
eventually obviate the need for immunohistochemical staining in PGL/PC, many 
patients in South Africa currently do not have access to genetic testing upon 
diagnosis of a PC or PGL as this is still costly and not widely available.  




laboratories, is relatively affordable, and can be used to assess the need for further 
targeted germline testing.  Interpretation of immunohistochemistry is part of routine 
training as a pathologist in South Africa and based on our reported inter-observer 
variability we expect that general pathologists in our setting would be capable of 




The limitations of this study are the small sample size and the lack of confirmatory 
testing of cases which showed loss of staining on immunohistochemistry by 
sequencing or germline testing.  Based on the published literature, the use of the 
immunohistochemical stain is an excellent surrogate marker for SDH mutation 
however this has not been proven in our setting. 
 
Future studies using a larger sample size, perhaps with multicentre data from 
various centres in South Africa, may help to generate statistically significant results.  
Although sequencing or germline testing is costly, a study which correlates SDH 
mutation status with SDHB immunohistochemical staining will be of value in 











7.1. Summary of findings  
 
Fifty-two cases of PC and PGL were identified at Tygerberg Hospital NHLS between 
2005 and 2015.  The prevalence of SDH deficiency in these cases based on 
immunohistochemical staining for SDHB is 36%.  Head and neck paragangliomas 
made up 50% of the sample with 46% occurring at thoraco-abdominal sites and 4% 
were spinal.  There was no statistically significant correlation between loss of 
staining and tumour site.  Patients who had loss of staining were significantly 
younger than those who had retained staining (z = -3.59, p < .001).  There was no 
association between sex and loss of staining.  Sixty-five percent of cases occurred in 
females with the majority of head and neck cases (73%) being female.  The number 
of cases with metastatic disease was too few to generate statistically significant 
results.  All three cases that had metastatic disease had loss of SDHB staining.  The 
inter-observer agreement in interpretation of the SDHB immunohistochemical stain 
was excellent (Cohen’s kappa = 0.917, p < .001).           
 
7.2. Conclusions  
 
Our findings largely correlate with the literature with our prevalence rate of 36% 
falling within the reported ranges (15-54%).17,25  The correlation between age and 
retention of staining is also in keeping with what would be expected as familial 
PGL/PC occur at a younger age.  The inter-observer agreement in IHC interpretation 
was excellent in this study, similar to other studies performed in more specialised 





7.3. Summary of contributions  
 
To the authors’ knowledge this is the first study that has assessed the prevalence of 
SDH deficiency in PGL/PC in South Africa.  Based on our findings of a similar rate of 
SDH deficiency in these tumours as in the published literature, we can recommend 
that this stain is useful to perform in our setting.  Access to genetic testing is limited 
in South Africa while IHC is widely available, cost effective and relatively easy to 
interpret.  Our reported inter-observer variability, which mirrors that of rates 
published by highly specialised centres, highlights that although sometimes 
challenging to interpret, with the correct guidelines, other generalist pathologists in 
our setting should be able to achieve similar results.  This test will therefore be a 
useful surrogate marker of SDH deficiency and should be made available to 
practicing pathologists in our setting to perform routinely on all PC/PGL cases.  
 
7.4. Future research 
 
There is a need for a larger study with a larger sample size in order to generate more 
statistically significant results.  A multi-institutional study pooling cases from centres 
across the country would be ideal.  Although access to genetic testing is limited, a 
study correlating loss of SDHB staining with germline SDH mutation status should 
ideally be performed in our setting to validate the correlation of the stain with the 







 Succinate dehydrogenase immunohistochemistry should be performed 
routinely on all PC/PGL cases in our setting in order to screen for syndromic 
associations and for prognostic information. 
 The SDH immunohistochemical stain should be made available to general 
pathologists practicing in the NHLS. 
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